Loading the player...
Closed Captioning / Subtitles Available
Information
Integrating Psychedelics Into Your Practice
Copyright :
Imagine a therapy session where your client brings up an interest in using psychedelics as part of their healing journey; after all, the options are getting plenty of mainstream attention. Are you prepared to guide them through the maze of information, potential benefits, and risks? This workshop addresses the increasing curiosity about psychedelic-assisted therapy and equips you with the knowledge and tools to respond effectively. You’ll review cutting-edge research of psychedelic compounds like MDMA and psilocybin, illustrating how these substances are reshaping treatment approaches for addiction and trauma. You’ll also explore practical ways to translate groundbreaking research into meaningful clinical practice, ensuring your clients receive informed, balanced, and ethical guidance. You’ll discover:
- An overview of the therapeutic potential of psychedelic compounds
- The latest developments in clinical trials and their implications for the future of psychotherapeutic treatment.
- Specific techniques for integrating psychedelic experiences into clinical practice, from assessment considerations to obtaining licenses and approvals.
- How to have balanced, informed discussions with clients about their interest or experiences with psychedelics, fostering a safe and supportive therapeutic environment.
- Up-to-date information on training, ethical issues, and valuable resources to support your clients effectively
Elizabeth Nielson, PhD
Elizabeth Nielson, PhD, is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a Site Co-Principal Investigator and therapist for an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and has served as a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, psilocybin-assisted treatment of treatment resistant depression, and earlier phase 2 and 3 trials of MDMA-assisted psychotherapy. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.
Speaker Disclosures:
Financial: Elizabeth Nielson is co-founder and lead trainer with Fluence International, Inc. She is a stock holder with Beckley Psytech and Sansero Life Sciences. Elizabeth Nielson receives a speaking honorarium from PESI, Inc.
Non-financial: Elizabeth Nielson has no relevant non-financial relationships.
